Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells.

Lamorte D, Faraone I, Laurenzana I, Milella L, Trino S, De Luca L, Del Vecchio L, Armentano MF, Sinisgalli C, Chiummiento L, Russo D, Bisaccia F, Musto P, Caivano A.

Int J Mol Sci. 2018 Oct 26;19(11). pii: E3348. doi: 10.3390/ijms19113348.

2.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2018 Oct 23. doi: 10.1007/s00277-018-3524-1. [Epub ahead of print]

PMID:
30353388
3.

Functionalized Gold Nanoparticles as Biosensors for Monitoring Cellular Uptake and Localization in Normal and Tumor Prostatic Cells.

Pannico M, Calarco A, Peluso G, Musto P.

Biosensors (Basel). 2018 Oct 4;8(4). pii: E87. doi: 10.3390/bios8040087.

4.

Global methylation patterns in primary plasma cell leukemia.

Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, Bollati V, Zoppoli P, Neri A, Musto P.

Leuk Res. 2018 Oct;73:95-102. doi: 10.1016/j.leukres.2018.09.007. Epub 2018 Sep 18.

PMID:
30257227
5.

Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.

D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, Musto P, Iorio EL, Ruggieri V.

Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317. [Epub ahead of print]

PMID:
30234409
6.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
7.

Meningeal Involvement in Primary Plasma Cell Leukemia.

D'Arena G, Bitetti C, Daraia B, Pietrantuono G, Musto P.

Indian J Hematol Blood Transfus. 2018 Jul;34(3):556-557. doi: 10.1007/s12288-018-0943-z. Epub 2018 Mar 12. No abstract available.

PMID:
30127574
8.

Effects of erythropoiesis-stimulating agents on overall survival of IPSS low/INT-1 risk, transfusion independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2018 Aug 3. pii: haematol.2017.183590. doi: 10.3324/haematol.2017.183590. [Epub ahead of print] No abstract available.

9.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

PMID:
30038381
10.

Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies.

Laurenzana I, Lamorte D, Trino S, De Luca L, Ambrosino C, Zoppoli P, Ruggieri V, Del Vecchio L, Musto P, Caivano A, Falco G.

Stem Cells Int. 2018 May 27;2018:9863194. doi: 10.1155/2018/9863194. eCollection 2018. Review.

11.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
12.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
13.

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Musto P.

Oncologist. 2018 May;23(5):511-515. doi: 10.1634/theoncologist.2018-0097. Epub 2018 Apr 26. No abstract available.

14.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
15.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. [Epub ahead of print]

PMID:
29602219
16.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
17.

Pseudomembranous colitis in acute lymphoblastic leukaemia.

D'Arena G, Pietrantuono G, Musto P.

Postgrad Med J. 2018 Jun;94(1112):361. doi: 10.1136/postgradmedj-2018-135605. Epub 2018 Mar 2. No abstract available.

PMID:
29500180
18.

Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D.

J Immunol Res. 2017;2017:1832968. doi: 10.1155/2017/1832968. Epub 2017 Dec 21. Review.

19.

MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.

Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P, De Luca L.

Int J Mol Sci. 2018 Feb 3;19(2). pii: E460. doi: 10.3390/ijms19020460. Review.

20.

Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.

Cosimato V, Scalia G, Raia M, Gentile L, Cerbone V, Visconte F, Statuto T, Valvano L, D'Auria F, Calice G, Graziano D, Musto P, Del Vecchio L.

Leuk Lymphoma. 2018 Sep;59(9):2242-2245. doi: 10.1080/10428194.2017.1416366. Epub 2018 Jan 15. No abstract available.

PMID:
29334284
21.

Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.

Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A.

Bone Marrow Transplant. 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12.

PMID:
29330395
22.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

PMID:
29263440
23.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

24.

Unusual Hypergranular Myelomatous Plasma Cells.

D'Arena G, Musto P.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):617-618. doi: 10.1007/s12288-017-0786-z. Epub 2017 Jan 30. No abstract available.

PMID:
29075080
25.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.

Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.

PMID:
28838276
26.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

27.

Octupolar Metastructures for a Highly Sensitive, Rapid, and Reproducible Phage-Based Detection of Bacterial Pathogens by Surface-Enhanced Raman Scattering.

Rippa M, Castagna R, Pannico M, Musto P, Borriello G, Paradiso R, Galiero G, Bolletti Censi S, Zhou J, Zyss J, Petti L.

ACS Sens. 2017 Jul 28;2(7):947-954. doi: 10.1021/acssensors.7b00195. Epub 2017 Jun 20.

PMID:
28750539
28.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M.

J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.

29.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

PMID:
28721629
30.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

31.

Do we need to distinguish exosomes from microvesicles in hematological malignancies?

Caivano A, Del Vecchio L, Musto P.

Leukemia. 2017 Sep;31(9):2009-2010. doi: 10.1038/leu.2017.205. Epub 2017 Jun 28. No abstract available.

PMID:
28656959
32.

Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL.

Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.

PMID:
28646624
33.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation).

Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. No abstract available.

34.

Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy.

Caivano A, La Rocca F, Laurenzana I, Trino S, De Luca L, Lamorte D, Del Vecchio L, Musto P.

Int J Mol Sci. 2017 Jun 2;18(6). pii: E1183. doi: 10.3390/ijms18061183. Review.

35.

Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.

De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, La Rocca F, Caivano A, Villani O, Cilloni D, Musto P, Del Vecchio L.

Cell Death Dis. 2017 Jun 1;8(6):e2849. doi: 10.1038/cddis.2017.253.

36.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.

PMID:
28541409
37.

Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?

De Luca L, Trino S, Laurenzana I, Lamorte D, Caivano A, Del Vecchio L, Musto P.

Int J Mol Sci. 2017 May 9;18(5). pii: E1022. doi: 10.3390/ijms18051022. Review.

38.

Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.

D'Auria F, La Rocca F, Simeon V, Statuto T, Pietrantuono G, D'Arena G, Villani O, Mansueto G, Traficante A, Musto P.

Br J Haematol. 2018 May;181(4):550-552. doi: 10.1111/bjh.14662. Epub 2017 Apr 25. No abstract available.

PMID:
28439880
39.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.

Int J Mol Sci. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837.

40.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
41.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

42.

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

D'Arena G, Simeon V, Laurenti L, Cimminiello M, Innocenti I, Gilio M, Padula A, Vigliotti ML, De Lorenzo S, Loseto G, Passarelli A, Di Minno MND, Tucci M, De Feo V, D'Auria F, Silvestris F, Di Minno G, Musto P.

Leuk Lymphoma. 2017 Nov;58(11):2633-2641. doi: 10.1080/10428194.2017.1306648. Epub 2017 Apr 3.

PMID:
28367662
43.

Local Structure and Dynamics of Water Absorbed in Poly(ether imide): A Hydrogen Bonding Anatomy.

de Nicola A, Correa A, Milano G, La Manna P, Musto P, Mensitieri G, Scherillo G.

J Phys Chem B. 2017 Apr 13;121(14):3162-3176. doi: 10.1021/acs.jpcb.7b00992. Epub 2017 Apr 4.

PMID:
28335602
44.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

45.

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.

Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schiødt M, Lakatos P, Taylor T, De Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P; GENVABO Consortium, Fedele S.

Oral Dis. 2017 May;23(4):477-483. doi: 10.1111/odi.12632. Epub 2017 Mar 6.

PMID:
28039941
46.

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Trino S, De Luca L, Laurenzana I, Caivano A, Del Vecchio L, Martinelli G, Musto P.

Front Pharmacol. 2016 Dec 16;7:491. doi: 10.3389/fphar.2016.00491. eCollection 2016. Review.

47.

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.

Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23.

PMID:
28008174
48.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F.

Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.

49.

A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies.

Laurenzana I, Caivano A, La Rocca F, Trino S, De Luca L, D'Alessio F, Schenone S, Falco G, Botta M, Del Vecchio L, Musto P.

Front Pharmacol. 2016 Nov 7;7:416. eCollection 2016.

50.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Review. Erratum in: Ann Oncol. 2017 May 24;:.

Supplemental Content

Support Center